Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution ...

Preliminary results show that, while Lagevrio hastened the time to recovery from COVID-19 by around six days, it was no better than placebo at keeping patients out of hospital.

The drug is also approved in Singapore. Xocova belongs to the same class of drugs as Pfizer’s (PFE) Paxlovid and Merck’s (MRK ...

Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

While prescription antiviral medications such as Paxlovid (nirmatrelvir with ritonavir) or Lagevrio (molnupiravir) are geared ...

Only about 5.3% of people with COVID-19 had been treated with an outpatient antiviral, such as nirmatrelvir-ritonavir (Paxlovid), molnupiravir (Lagevrio), or remdesivir (Veklury). In contrast ...

With changing recommendations and multiple seasonal viruses to contend with, here’s your simple guide to the 2024-2025 cold and flu season and when to call your doctor.

The underlying core business looks solid, with operational sales growth of 8% (excluding Lagevrio), led by cancer drug Keytruda (up 17%). Merck’s steady pipeline innovation, especially the ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.